The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4): A novel strategy for the treatment of melanoma and other malignancies
Abstract
Cancer immunotherapy centers on modulating the host's tumor‐directed immune response. One promising approach involves augmentation of cell‐mediated immunity by interrupting T‐cell pathways responsible for immune down‐regulation or tolerance. The discovery of cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) and its role as a key negative regulator for T cells has prompted efforts to target this signaling molecule to improve cancer therapy. Activation, or ‘priming’, of naive T cells in response to tumor‐cell invasion comprises a dual‐signaling mechanism. Signal 1 requires tumor‐associated antigen recognition by the T‐cell receptor, while signal 2 occurs through binding of CD80 or CD86 (B7.1 of 2) on the antigen presenting cell (APC) with CD28 on the T cell. Importantly, there is a final step responsible for naturally occurring immune regulation; this occurs in response to competitive binding of CD80/CD86 on the APC by CTLA‐4 on the T cell. This ‘immune checkpoint’ interrupts signal 2 and inhibits the activated T cell. Targeting CTLA‐4 as an anticancer strategy: Following proof‐of‐concept studies in animals, fully human anti‐CTLA‐4 antibodies were developed and 2 are undergoing clinical evaluation. Ipilimumab and tremelimumab have shown promising antitumor activity, initially in patients with advanced melanoma. Class‐specific immune‐related adverse events (irAEs) were common and mostly transient and/or manageable. These events are thought to be mechanism‐of‐action‐related, indicating immune tolerance is broken; this relation may also explain the association between irAEs and response seen in several trials. Interruption of immune inhibitory pathways via CTLA‐4 blockade appears to be a promising strategy for cancer immunotherapy. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135
IMMUNOBIOLOGY : the immunesystem in health and disease
Janeway, C. A. (1994) · Cited by 1,757
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 1×
“In a preliminary study, ipilimumab (3 mg/kg Q3W) in combination with vaccination with 2 human leukocyte antigen (HLA) class I-restricted peptides from the gp100 melanoma-associated antigen gave 2 complete and 1 partial response in 14 patients (21% response rate) with metastatic melanoma.(54) Finally, in a phase 1 and…”
BackgroundA new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 2×
“The addition of anti-CTLA-4 monoclonal antibody to vaccination enhanced T-cell activation and memory.(38) This is likely to be because CTLA-4 blockade either increased the magnitude of the immune”
BackgroundAttia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 998
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5022.779 · Cited by 810
Blank, C., Gajewski, T. F., & Mackensen, A. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 637
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 445
CD28/B7 Costimulation: A Review
Greenfield, E. A., Nguyen, K. A., & Kuchroo, V. K. (1998) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v18.i5.10 · Cited by 441
Immune resistance orchestrated by the tumor microenvironment
Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437
Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 434
Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T. N., Choi, E. M., Greenberg, N. M., Burg, M. B., & Allison, J. P. (2000) · PubMed · Cited by 425
CTLA-4 in autoimmune diseases – a general susceptibility gene to autoimmunity?
Kristiansen, O., Larsen, Z., & Pociot, F. (2000) · Genes & Immunity · doi:10.1038/sj.gene.6363655 · Cited by 414
Hurwitz, A. A., Yu, T. F.-Y., Leach, D. R., & Allison, J. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10067 · Cited by 378
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Maker, A. V., Attia, P., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7746 · Cited by 343
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Mapara, M. Y., & Sykes, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.041 · Cited by 325
Positron Emission Tomography As an Imaging Biomarker
Weber, W. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6068 · Cited by 312
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M., Yellin, M. J., Haworth, L. R., Levy, C., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 265
Donner, H., Braun, J., Seidl, C., Rau, H., Finke, R., Ventz, M., Walfish, P. G., Usadel, K. H., & Badenhoop, K. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4406 · Cited by 241
T-cell costimulation–biology, therapeutic potential, and challenges.
Sharpe, A. H., & Abbas, A. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068087 · Cited by 206
Natural T cell immunity against cancer.
Nagorsen, D., Scheibenbogen, C., Marincola, F. M., Letsch, A., & Keilholz, U. (2003) · PubMed · Cited by 196
CTLA-4 and its role in autoimmune thyroid disease
Chistiakov, D., & Turakulov, R. I. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0310021 · Cited by 163
MOKYR, M. B., Kalinichenko, T. V., Gorelik, L., & Bluestone, J. A. (1998) · PubMed · Cited by 147
Reuben, J. M., Lee, B.-N., Li, C., Gómez-Navarro, J., Bozon, V. A., Parker, C. A., Hernandez, I. M., Gutiérrez, C., Lopez‐Berestein, G., & Camacho, L. H. (2006) · Cancer · doi:10.1002/cncr.21854 · Cited by 145
Vaidya, B., Pearce, S. H. S., Charlton, S., Marshall, N., Rowan, A. D., Griffiths, I. D., Kendall-Taylor, P., Cawston, T. E., & Young-Min, S. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.2.180 · Cited by 135
Donner, H. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4130 · Cited by 131
Gregor, P. D., Wolchok, J. D., Ferrone, C. R., Buchinshky, H., Guevara-Patino, J. A., Perales, M., Mortazavi, F., Bacich, D. J., Heston, W., Latouche, J., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.10.048 · Cited by 127
Ishikawa, T., Fujita, T., Suzuki, Y., Okabe, S., Yuasa, Y., Iwai, T., & Kawakami, Y. (2003) · PubMed · Cited by 117
Blomhoff, A., Lie, B. A., Myhre, A. G., Kemp, E. H., Weetman, A. P., Akselsen, H. E., Huseby, E. S., & Undlien, D. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031854 · Cited by 115
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman, A. J., Yellin, M. J., & Keler, T. (2005) · PubMed · Cited by 80
Anti-CD137 Antibodies in the Treatment of Autoimmune Disease and Cancer
Mittler, R. S., Foell, J. L., McCausland, M. M., Strahotin, S., Niu, L., Bapat, A. S., & Hewes, L. B. (2004) · Immunologic Research · doi:10.1385/ir:29:1-3:197 · Cited by 62
Zalloua, P., Abchee, A., Shbaklo, H., Zreik, T. G., Terwedow, H. A., Halaby, G., & Azar, S. T. (2004) · Human Immunology · doi:10.1016/j.humimm.2004.04.007 · Cited by 54
Fischkoff, S. A., Hersh, E. M., Weber, J. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7525 · Cited by 49
Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
Morse, M. A. (2005) · PubMed · Cited by 48
Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma
Hamid, O., Urba, W. J., Yellin, M. J., Nichol, G., Weber, J. S., Hersh, E. M., Tchekmedyian, S., Hodi, F. S., Weber, R. W., & O'Day, S. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8525 · Cited by 41
Self-citationDendritic Cells: Immune Saviors or Achilles' Heel?
Cutler, C. W., Jotwani, R., & Pulendran, B. (2001) · Infection and Immunity · doi:10.1128/iai.69.8.4703-4708.2001 · Cited by 39
Ribas, A., Antonia, S. J., Sosman, J. A., Kirkwood, J. M., Redman, B. G., Gajewski, T. F., Pavlov, D., Bulanhagui, C. A., Navarro, J. G., & Camacho, L. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3000 · Cited by 38
Weber, J. S., Targan, S. R., Scotland, R., Snively, J., Garcia, M., Yellin, M. J., Fischkoff, S. A., & Nichol, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.2510 · Cited by 38
Weber, J. S., Hersh, E. M., Yellin, M. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8523 · Cited by 37
The stromal component of the marrow microenvironment is not derived from the malignant clone in MDS
Ramakrishnan, A., Awaya, N., Bryant, E. M., et al. (2006) · Blood · doi:10.1182/blood-2006-02-001479 · Cited by 31
The Therapeutic Potential of 4-1BB (CD137) in Cancer
Nam, K.-O., Kang, W., Kwon, B., Kim, S., & Lee, H.-W. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009054629681 · Cited by 21
Gómez-Navarro, J., Antonia, S. J., Sosman, J. A., Kirkwood, J. M., Redman, B. G., Gajewski, T. F., Pavlov, D., Bulanhagui, C. A., Ribas, A., & Camacho, L. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8524 · Cited by 19
Gerritsen, W. R., van den Eertwegh, A. J. M., de Gruijl, T. D., Giaccone, G., Scheper, R. J., Sacks, N., Harding, T. C., Lowy, I., Stankevich, E., & Hege, K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5120 · Cited by 15
Fong, L. H., Kavanagh, B., Hou, Y., O’Brien, S., Valiente, J., WEINBERG, V. K., Rini, B. I., & Small, E. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3001 · Cited by 12
Chung, K. Y., Gore, I., Fong, L. H., Venook, A. P., Dorazio, P., Healey, D. I., Pavlov, D., & Saltz, L. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3035 · Cited by 6
Efficacy of anti-CTLA-4 antibody in the SA1N tumor model when combined with dexamethasone
Chen, B., Phillips, J., Greenbaum, M., Klitzing, D., Cardarelli, P. M., & Korman, A. J. (2007) · Cancer Research · Cited by 5
Cited by
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Metadata
- Authors
- O'Day, S. J., Hamid, O., & Urba, W. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-11-14
- Volume
- 110
- Issue
- 12
- Pages
- 2614-2627
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2020727013
- Cited by
- 309
- References
- 67
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.